Exendin-4 regulates redox homeostasis in rats fed with high-fat diet

Acta Biochimica et Biophysica Sinica

Volumn 47, Issue 6, 2015, Pages 397-403

  Niu, Shiwei ^a   Wang, Liqiong ^b   He, Ming ^a   Peng, Yunzhu ^a   Li, Shude ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b Yan'an Hospital   (China)

Author keywords

Cystathionine beta synthase; Exendin 4; Homocysteine; MicroRNA; Non alcoholic fatty liver disease; Redox homeostasis

Indexed keywords

CYSTATHIONINE BETA SYNTHASE; EXENDIN 4; GLUTATHIONE; HOMOCYSTEINE; MALONALDEHYDE; MESSENGER RNA; PEPTIDE; VENOM;

ANIMAL; BLOOD; DOWN REGULATION; GENETICS; HOMEOSTASIS; LIPID DIET; MALE; METABOLISM; NONALCOHOLIC FATTY LIVER; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; CYSTATHIONINE BETA-SYNTHASE; DIET, HIGH-FAT; DOWN-REGULATION; GLUTATHIONE; HOMEOSTASIS; HOMOCYSTEINE; MALE; MALONDIALDEHYDE; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATION-REDUCTION; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; VENOMS;

EID: 84941551523     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmv027     Document Type: Article

References (36)

1. Stead LM, Brosnan ME, Brosnan JT. Characterization of homocysteine metabolism in the rat liver. Biochem J 2000, 350 (Pt 3) : 685-692.
2. Zou CG, Banerjee R. Homocysteine and redox signaling. Antioxid Redox Signal 2005, 7: 547-559.
3. Zou CG, Banerjee R. Tumor necrosis factor-alpha-induced targeted proteolysis of cystathionine beta-synthase modulates redox homeostasis. J Biol Chem 2003, 278: 16802-16808.
4. Schulz RJ. Homocysteine as a biomarker for cognitive dysfunction in the elderly. Curr Opin Clin Nutr Metab Care 2007, 10: 718-723.
5. Liu WJ, Ma LQ, Liu WH, ZhouW, Zhang KQ, Zou CG. Inhibition of hepatic glycogen synthesis by hyperhomocysteinemia mediated by TRB3. Am J Pathol 2011, 178: 1489-1499.
6. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346: 1221-1231.
7. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010, 51: 1820-1832.
8. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007, 191: 235-240.
9. Gulsen M, Yesilova Z, Bagci S, Uygun A, Ozcan A, Ercin CN, Erdil A, et al. Elevated plasma homocysteine concentrations as a predictor of steatohepatitis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2005, 20: 1448-1455.
10. Kalhan SC, Guo L, Edmison J, Dasarathy S, McCullough AJ, Hanson RW, Milburn M. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 2011, 60: 404-413.
11. Bravo E, Palleschi S, Aspichueta P, Buque X, Rossi B, Cano A, Napolitano M, et al. High fat diet-induced non alcoholic fatty liver disease in rats is associated with hyperhomocysteinemia caused by down regulation of the transsulphuration pathway. Lipids Health Dis 2011, 10: 60.
12. ZhangW, He H,Wang H,Wang S, Li X, Liu Y, Jiang H, et al. Activation of transsulfuration pathway by salvianolic acid a treatment: A homocysteinelowering approach with beneficial effects on redox homeostasis in high-fat diet-induced hyperlipidemic rats. Nutr Metab (Lond) 2013, 10: 68.
13. Yun KU, Ryu CS, Oh JM, Kim CH, Lee KS, Lee CH, Lee HS, et al. Plasma homocysteine level and hepatic sulfur amino acid metabolism in mice fed a high-fat diet. Eur J Nutr 2013, 52: 127-134.
14. Chang XX, Yan HM, Xu Q, XiaMF, Bian H, Zhu TF, Gao X. The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet. Lipids Health Dis 2012, 11: 86.
15. Dahlhoff C, Desmarchelier C, Sailer M, Furst RW, Haag A, Ulbrich SE, Hummel B, et al. Hepatic methionine homeostasis is conserved in C57BL/ 6N mice on high-fat diet despite major changes in hepatic one-carbon metabolism. PLoS One 2013, 8: E57387.
16. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagonlike protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006, 43: 173-181.
17. Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z, Barzilai N, et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol 2011, 54: 1214-1223.
18. Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, De Minicis S, Candelaresi C, Faraci G, et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 2011, 31: 1285-1297.
19. Tomas E, Stanojevic V, Habener JF. GLP-1-derived nonapeptide GLP-1 (28-36) amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul Pept 2011, 167: 177-184.
20. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008, 24: 275-286.
21. Fraga CG, Leibovitz BE, Tappel AL. Lipid peroxidation measured as thiobarbituric acid-reactive substances in tissue slices: Characterization and comparison with homogenates and microsomes. Free Radic Biol Med 1988, 4: 155-161.
22. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta 1979, 582: 67-78.
23. Mosharov E, Cranford MR, Banerjee R. The quantitatively important relationship between homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its regulation by redox changes. Biochemistry 2000, 39: 13005-13011.
24. Xu F, Li Z, Zheng X, Liu H, Liang H, Xu H, Chen Z, et al. SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis. Diabetes 2014, 63: 3637-3646.
25. Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One 2011, 6: E25269.
26. Dahlhoff C, Worsch S, Sailer M, Hummel BA, Fiamoncini J, Uebel K, Obeid R, et al. Methyl-donor supplementation in obese mice prevents the progression of NAFLD, activates AMPK and decreases acyl-carnitine levels. Mol Metab 2014, 3: 565-580.
27. Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol 2008, 8: 923-934.
28. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997, 46: 3-10.
29. Donath MY, Dalmas E, Sauter NS, Boni-Schnetzler M. Inflammation in obesity and diabetes: Islet dysfunction and therapeutic opportunity. Cell Metab 2013, 17: 860-872.
30. Gezginci-Oktayoglu S, Sacan O, Yanardag R, Karatug A, Bolkent S. Exendin-4 improves hepatocyte injury by decreasing proliferation through blocking NGF/TrkA in diabetic mice. Peptides 2011, 32: 223-231.
31. Monji A, Mitsui T, Bando YK, Aoyama M, Shigeta T, Murohara T. Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes. Am J Physiol Heart Circ Physiol 2013, 305: H295-H304.
32. Sekhar RV, McKay SV, Patel SG, Guthikonda AP, Reddy VT, Balasubramanyam A, Jahoor F. Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine. Diabetes Care 2011, 34: 162-167.
33. Mahmoud AM, Ashour MB, Abdel-Moneim A, Ahmed OM. Hesperidin and naringin attenuate hyperglycemia-mediated oxidative stress and proinflammatory cytokine production in high fat fed/streptozotocin-induced type 2 diabetic rats. J Diabetes Complications 2012, 26: 483-490.
34. Guarino MP, Macedo MP. Co-administration of glutathione and nitric oxide enhances insulin sensitivity in Wistar rats. Br J Pharmacol 2006, 147: 959-965.
35. Kim BS, Cha HN, Kim YW, Kim JY, Dan JM, Park SY. Inhibition of lipid infusion-induced skeletal muscle insulin resistance by cotreatment with tempol and glutathione in mice. J Pharmacol Sci 2009, 110: 370-380.
36. Hoehn KL, Salmon AB, Hohnen-Behrens C, Turner N, Hoy AJ, Maghzal GJ, Stocker R, et al. Insulin resistance is a cellular antioxidant defense mechanism. Proc Natl Acad Sci USA 2009, 106: 17787-17792.